The following is written by Sheldon S. Sones, RPh, FASCP, President, Sheldon S. Sones and Associates. Monoamine oxidase inhibitors (MAO inhibitors or MAOIs) are drugs which, by virtue of their ...

Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively ...

Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack ...

Miralogx LLC and Mira Pharmaceuticals Inc. have jointly disclosed new cannabinoid analogues acting as monoamine oxidase-A (MAO-A) and/or MAO-B inhibitors reported to be useful for the treatment of ...

In the years after World War II, there were no effective medicines for schizophrenia, bipolar disorder, or major depression. There were not even names for such things. The word ‘antipsychotic’ was ...

Monoamine oxidase inhibitors (MAOIs) have a long and prosperous history as medications for major depressive disorder (MDD). But this type of antidepressant has mostly seen its day. Though MAOIs are ...

DEAR PEOPLE’S PHARMACY: You wrote recently about MAO inhibitors as antidepressants. I hope they become more widely available. No other antidepressant has worked for me for 25 years. I’ve tried ...